viewZelira Therapeutics Ltd

Zelda Therapeutics on rapid path to medicinal cannabis commercialisation

The company has a focus on clinical validation and is well placed to service a rapidly growing market.

Zelda presents at CEO Session
Managing director Dr Richard Hopkins presents at the CEO Session in Melbourne

Zelda Therapeutics Ltd (ASX:ZLD) is on a rapid path to commercialisation of its medicinal cannabis products aimed at treating pain, anxiety, sleep apnea and cancer.

The company’s managing director Dr Richard Hopkins told investors at this week’s Proactive CEO Sessions in Sydney and Melbourne that the company is well placed to service a rapidly growing global market.

READ: Zelda Therapeutics to use Federal Government R&D tax rebate of $769,000 to drive clinical trials

He said the company was building a portfolio of clinically validated assets which presented multiple revenue opportunities to license and generate milestone and royalty payments.

This strategy was well advanced because the company had a singular focus on clinical validation to address key unmet needs.

Market dynamics

Among the interesting medicinal cannabis market dynamics outlined were:

  • Medicinal cannabis is legal in more than 34 countries and in 35 US states;
  • Only around 1% of the population in the US and Canada is registered to use medicinal cannabis;
  • The medicinal cannabis market is forecast to grow to $40-55 billion by 2028 (18% CAGR);
  • Around US$20 billion has been raised by medicinal cannabis companies over the last four years; and
  • 21 kilograms is the amount of cannabis required to consume for a lethal dose.

Zelda has a number of upcoming catalysts including results of three first-in-class clinical trials, an insomnia trial, observational autism trial and opioid reduction trial, which are due in the second half of 2019.

Among the recent highlights are an expanded pre-clinical program for cancers and cognitive decline, and a manufacture and German distribution agreement with Hapa Medical BV.

Zelda has also established partnerships with US-based Ilera Healthcare to access more than 110,000 patients and with Suda to develop proprietary oral mucosal formulations.

Read Dr Richard Hopkins presentation.

Quick facts: Zelira Therapeutics Ltd

Price: 0.053 AUD

Market: ASX
Market Cap: $60.54 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...



Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 02/21/2020

2 min read